Systemic Therapy
➤ In the setting of patients undergoing adjuvant radiotherapy, the addition
of concurrent chemotherapy may not be routinely offered outside of a
clinical trial. (Moderate recommendation; EB-L)
➤ In the setting of patients undergoing radiotherapy for non-operable
salivary gland cancer, the addition of concurrent chemotherapy
may not be routinely offered outside of a clinical trial. (Moderate
recommendation; IC-Ins)
➤ In patients with salivary gland tumors expressing androgen receptor and/
or Her2-Neu, adjuvant endocrine or targeted therapy may not be routinely
offered outside of a clinical trial. (Moderate recommendation; IC-Ins)
Follow-up Evaluations
➤ Clinical follow-up with history and physical exam should be completed
on a regular basis with decreasing frequency as time elapses
from completion of treatment of salivary gland cancer. (Moderate
recommendation; IC-I)
➤ Post-treatment baseline imaging with contrast CT or MRI (for patients
without contraindications) of the primary site, and/or PET/CT should
be obtained 3 months after completion of all treatment. (Moderate
recommendation; IC-L)
➤ Follow-up surveillance imaging of the primary site (contrast CT or MRI)
and the chest CT may be obtained every 6–12 months for the first 2 years
after treatment. (Moderate recommendation; IC-L)
➤ Follow-up imaging of the primary site and the chest from years 3–5
should be directed by symptoms and physical exam findings. Yearly
follow-up imaging may be offered in cases of high-grade histology or poor
prognostic clinicopathologic features. (Moderate recommendation; IC-L)
➤ Long-term follow-up (beyond 5 years) with yearly exam should be offered
in all salivary gland cancer patients. Yearly chest CT may be offered
especially in patients with high-grade histology or poor prognostic
clinicopathologic features. (Moderate recommendation; IC-L)
